Printer Friendly

MEDCO RESEARCH'S ATP ANTICANCER DRUG MOVES TO CLINICAL TRIALS

 MEDCO RESEARCH'S ATP ANTICANCER DRUG MOVES TO CLINICAL TRIALS
 LOS ANGELES, Calif., Sept. 22 /PRNewswire/ -- Medco Research, Inc. ("Medco") (AMEX: MRE) today announced that it is initiating Phase I clinical trials of adenosine triphosphate (ATP) for the treatment of advanced metastatic cancer and cancer-related cachexia (general ill health and malnutrition). The FDA-approved clinical trial will be under the direction of Dr. Charles M. Haskell, Director of the Wadsworth Veterans Administration Cancer Center, in Los Angeles.
 ATP has been the subject of growing scientific interest with several pre-clinical studies in the U.S. and abroad having confirmed ATP's potential anticancer activities. One such U.S. study was the subject of an article in the January 1992 issue of The Journal of Clinical Investigation by a group of investigators at the Division of Cancer Treatment of the National Cancer Institute. It reported that ATP provided significant inhibition of the growth of hormone-independent human prostate cancer cells in culture.
 ATP is an adenosine-containing natural substance present throughout the body and is the major source of intracellular energy in all living cells. The anticancer activities of ATP and its ability to prevent cancer-related weight loss as well as inhibit other adverse effects of cachexia in animals was first discovered by a scientific researcher, Dr. Eliezer Rapaport, from whom Medco has licensed U.S., European and Japanese patents for use of the drug against cancer.
 "Dr. Haskell is well known for his contributions in the field of clinical anticancer drug research, and will conduct the first Medco sponsored clinical trial of ATP in the treatment of cancer," said Archie Prestayko, Ph.D., President and CEO of Medco.
 The initial ATP study will be conducted in patients with advanced non-small cell lung cancer. Lung cancer will account for approximately 28 percent of the estimated 520,000 cancer-related deaths in the U.S. in 1992. Approximately 80 percent of lung cancers in the U.S. are non- small cell lung cancer. Assuming successful completion of this Phase I study, Medco intends to conduct clinical trials of ATP in patients with advanced prostate and colorectal cancers.
 Dr. Haskell said, "We are looking forward to beginning our clinical study of ATP. Patients with advanced non-small cell lung cancer have very few choices available to them in the way of chemotherapy, and we are hopeful that ATP will prove to be valuable for these and possibly other cancer patients."
 Medco Research is a pharmaceutical company engaged in the acquisition, research and development of new prescription drugs for the diagnosis or treatment of certain cardiovascular diseases and cancer.
 -0- 9/22/92
 /CONTACT: Archie W. Prestayko, Ph.D., Medco Research, Inc., 213-966-4148, or Steven Anreder of Anreder and Company, 212-421-4020, Medco Research/
 (MRE) CO: Medco Research, Inc. ST: California IN: MTC SU:


SH -- NY016 -- 2008 09/22/92 08:52 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 22, 1992
Words:470
Previous Article:GM REPORTS PRODUCTION INFORMATION
Next Article:BIOMERICA RECEIVES INVESTMENT IN ITS SUBSIDIARY
Topics:


Related Articles
MEDCO COMMENCES IPPA CLINICAL TRIAL
MEDCO RESEARCH LAUNCHES PHASE III TRIALS OF VIASCINT
MEDCO RESEARCH COMPLETES PHASE I ANTI-CANCER STUDY OF ATP
BURROUGHS WELLCOME MAKES INVESTIGATIONAL LUNG CANCER DRUG WIDELY AVAILABLE
XENOVA AND THE CANCER RESEARCH CAMPAIGN (CRC) TO COLLABORATE ON THE DEVELOPMENT OF NOVEL ANTICANCER COMPOUND
BIONUMERIK-CRAY RESEARCH PARTNERSHIP MOVES SUPERCOMPUTER-AIDED DRUG DESIGN INTO HUMAN CLINICAL TRIALS
MEDCO RESEARCH REPORTS POSITIVE RESULTS OF PHASE II CLINICAL TRIAL FOR ATP IN CANCER TREATMENT
MEDCO CARDIOVASCULAR PRODUCTS CAPTURE INTEREST OF U.S. CARDIOLOGISTS
ISIS INITIATES PHASE I CLINICAL TRIALS FOR A NOVEL ANTISENSE CANCER COMPOUND TO INHIBIT C- RAF KINASE INHIBITION
MEDCO RESEARCH FILES NDA FOR VIASCINT(TM)

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters